Ocular Melanoma Trials
Castle Biosciences – CLEAR Study – An open, 5-year registry study to track clinical application of DecisionDx-UM gene expression assay results and associated patient outcomes. This study is currently enrolling patients with uveal melanoma that have undergone class typing at the time of biopsy or if they have undergone enucleation in the past.
Iconic Therapeutics – ICON-1 – The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation of the affected eye. (Actively enrolling)